David Scott Miller


AuthID: R-00K-250

Publicações Confirmadas: 319



11
TÍTULO: Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTORES: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLICAÇÃO: 2025
INDEXADO EM: CrossRef
NO MEU: ORCID
12
TÍTULO: Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTORES: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLICAÇÃO: 2025
INDEXADO EM: CrossRef
NO MEU: ORCID
13
TÍTULO: Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTORES: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLICAÇÃO: 2025
INDEXADO EM: CrossRef
NO MEU: ORCID
14
TÍTULO: Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTORES: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLICAÇÃO: 2025
INDEXADO EM: CrossRef
NO MEU: ORCID
15
TÍTULO: Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTORES: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller ; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLICAÇÃO: 2025
INDEXADO EM: CrossRef
NO MEU: ORCID
16
TÍTULO: Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma
AUTORES: William Vintzileos; Hannah Beer; David Scott Miller ; Jayanthi Lea;
PUBLICAÇÃO: 2025, FONTE: Gynecologic Oncology Reports, VOLUME: 58
INDEXADO EM: Scopus CrossRef Unpaywall
NO MEU: ORCID
17
TÍTULO: Surgical Staging Identifies Occult Metastases in Over 50% of Uterine-Confined Carcinosarcoma
AUTORES: William Vintzileos; Hannah Beer; David Scott Miller ; Jayanthi Lea;
PUBLICAÇÃO: 2025
INDEXADO EM: CrossRef
NO MEU: ORCID
18
TÍTULO: 187 Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
AUTORES: Jalid Sehouli; Ignace Vergote; Erika Hamilton; Alejandro Pérez Fidalgo; Toon Van Gorp; Giovanni Scambia; Jaroslav Klat; Tally Levy; Stephen Welch; Debra L Richardson; Eva Maria Guerra Alía; Stéphanie Henry; Pauline Wimberger; David Scott Miller ; Jerónimo Martínez; Bradley J Monk; Pratheek Kalyanapu; Monsoor Raza Mirza; Vicky Makker;
PUBLICAÇÃO: 2024, FONTE: Oral Sessions
INDEXADO EM: CrossRef: 2
NO MEU: ORCID | CIÊNCIAVITAE
19
TÍTULO: Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).
AUTORES: Jung-Yun Lee; Baek-Yeol Ryoo; Jin Won Kim; Ann-Lii Cheng; Richard S Finn; Kosei Hasegawa; Vicky Makker; Masatoshi Kudo; David Scott Miller ; Philippe Merle; Susanna Varkey Ulahannan; Tetsuya Hosaka; Takatoshi Sahara; Cixin S He; Karen O'Hara; Lea Dutta; Toshiyuki Tamai; Masafumi Ikeda;
PUBLICAÇÃO: 2024, FONTE: Journal of Clinical Oncology, VOLUME: 42, NÚMERO: 16_suppl
INDEXADO EM: CrossRef
NO MEU: ORCID | CIÊNCIAVITAE
20
TÍTULO: Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study  Full Text
AUTORES: Vicky Makker; Jose Alejandro Perez Fidalgo; Giorgio Valabrega; Erika Hamilton; Toon Van Gorp; Jalid Sehouli; Klaudia Regináčová; Debra L Richardson; Tamar Perri; Amit M Oza; David Scott Miller ; Eva Maria Guerra Alía; Ugo De Giorgi; Stephanie Henry; Daniel L Spitz; Pauline Wimberger; Markéta Bednaříková; Hye Sook Chon; Jerónimo Martínez Garcia; Carmela Pisano; Jonathan S Berek; Ignacio Romero; Giovanni Scambia; Lorena Fariñas Madrid; Joseph Buscema; Fabienne Schochter; Kai Li; Pratheek Kalyanapu; Christopher J Walker; Ignace Vergote; ...Mais
PUBLICAÇÃO: 2024, FONTE: Gynecologic Oncology, VOLUME: 185
INDEXADO EM: Scopus CrossRef: 3
NO MEU: ORCID | CIÊNCIAVITAE
Página 2 de 32. Total de resultados: 319.

Um espaço para investigadores e suas Instituições

Links Úteis

Ajuda

© 2025 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service